Pneumonitis

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, offers advice to new residents seeing patients with EGFR-mutated lung cancer.

BOSTON — Patients with eosinophilic reactive airway disease after immune checkpoint inhibitor therapy saw improved symptoms with typical treatment for reactive airway disease, according to a study presented at the CHEST Annual Meeting.

Neoadjuvant atezolizumab prior to chemoradiation therapy exhibited promising activity for patients with unresectable stage III non-small cell lung cancer, according to results of a nonrandomized phase 2 study.

Melina Elpi Marmarelis, MD, discussed research on the use of osimertinib versus durvalumab following chemoradiation in patients with stage III EGFR-mutated NSCLC.

An inhaled potent thiodigalactoside galectin-3 inhibitor appeared well-tolerated among patients with COVID-19 pneumonitis, according to study results published in American Journal of Respiratory and Critical Care Medicine.

Drug-related pneumonitis occurred among 18% of patients receiving osimertinib for advanced epidermal growth factor receptor mutation-positive non-small cell lung cancer, according to study results published in CHEST.

Lung disease that patients with cancer experience from the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki can be treated effectively if detected early and managed promptly, according to study results published in ESMO Open.

In this video, Thomas Waddington, MD, assistant clinical professor in the department of medicine, division of pulmonary and critical care medicine at City of Hope National Medical Center, discusses what pulmonologists should be staying up to date on in terms of lung cancer treatments.

The Healio editors have compiled a list of the most-read news on interstitial lung diseases published in 2020.